Answers are grounded in this paper and cite their sources.
Retrospective audit reveals effective local control and low toxicity of SBRT in patients with oligometastases, suggesting future studies are needed.
e23333 Background: To retrospectively review the toxicity and early outcome data from patients who have received stereotactic body radiotherapy (SBRT) for extracranial oligometastases in our institution. Methods: Eligible patients had ≤3 extracranial metastases and performance status ≤2. Prior systemic therapy and radical treatment of oligometastastic relapse with any standard treatment modality was permitted. Follow-up consisted of clinical examination, and radiological assessments. RECIST criteria was used for defining progression events. Toxicity was evaluated using CTCAE v5.0. Local control, progression-free survival (PFS) and freedom from widespread distant metastasis were calculated. Results: Between August 2023 and April 2025, 22 patients with 43 metastases received SBRT (range 1–3 per patient). Most common sites were lymph nodes(19), liver(14) ad spine(10). The median follow-up was 12.5 months (range 0–20.4). The median PFS was 12.5 months (1 year PFS 57%); 1 year local control 96%. At 1 year, 76% of patients were free from widespread distant metastases. No ≥ grade 3 acute or late toxicity was observed. Conclusions: SBRT for extracranial oligometastases demonstrated excellent early local control with minimal toxicity. These findings warrant confirmation with longer follow-up and randomized controlled trials to determine the impact on survival outcomes when added to standard care.
No takes yet. Share an insight, caveat, or question.
Mahajan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: